Dec 30, 2009|
Stellar performance of pharma in 2009
After the dismal performance of pharma in 2007 and 2008, pharma stocks did well in 2009. While a broader stock market rally certainly helped matters, an improved performance in businesses did its job as well. Plus the defensive nature of healthcare stocks meant that in times of uncertainty investors chose to lap up stocks from this sector. In this article, we shall take a look at the star performers and the laggards and the outlook for the sector going forward.
Pharma: Winners and losers in 2009
||Jan 01, 2009
||Dec 30, 2009
Dr.Reddy's: Dr.Reddy's gained an impressive 143% since the start of this year and has easily emerged as the top performer amongst pharma stocks. The company did well during the first half of the year. The key contributors to growth have been the US, India and Russia and these will continue to enhance the company's performance in the future as well. Having said that, Betapharm in the German market has been under a lot of pressure due to changes in the regulatory landscape in that country and performance of this market in the near term looks uncertain. Dr.Reddy's custom manufacturing business which grew at a subdued pace during the first half is poised to do much better in the second half of this fiscal. Not just that, in the US generics market, Dr.Reddy's also stands to benefit from some product launches that have limited competition.
Lupin and Cadila: Lupin and Cadila were next in line with gains of 136% and 134% respectively. In Lupin's case, a strong performance during the first half of the year and the strengthening of its branded portfolio in the US were the key drivers. Given that the US generics market is highly competitive, Lupin's strategy of focusing on branded generics is expected to augur well due to limited competition and higher margins. Cadila's gains were also prompted by a healthy performance in 1HFY10 and robust growth in its domestic and export businesses.
Glenmark: Glenmark was at the receiving end during the year losing around 8%. The global economic slowdown had an adverse impact on its business especially during the last two quarters of FY09, although the scenario has improved since then. Setbacks in its R&D programme also did not help matters. Discontinuation of research on one molecule out-licensed to Eli Lilly and negative results with respect to its lead compound 'Oglemilast' out-licensed to Forest Laboratories were the setbacks that Glenmark had to contend with. Having said that, the company still has a strong R&D pipeline as compared to its peers and prospects seem to be improving as the financials for the last two quarters have shown.
2008 was a difficult year for the Indian pharma sector as many companies suffered due to the sharp depreciation of the rupee against the dollar resulting in them having to report huge forex losses. Plus the sagging business environment in both the developed and the semi regulated markets also played spoilsport. This scenario certainly improved in 2009 which witnessed a relatively stable forex exchange market. While the performance in the first two quarters was not much to write about, most of the managements were confident of a better second half. The prospects are certainly expected to be brighter in the coming year.
The fundamentals driving the pharma sector from a long term perspective have not changed. Pressure to reduce healthcare costs will keep up the demand for generics, a strategy now the global innovators are also adopting. Outsourcing will also gain momentum as global innovators look to prune costs meaning that those companies focusing on custom manufacturing will stand to benefit. Thus, from a long term perspective the prospects of the pharma sector are strong. However, many of the stocks have run up considerably this year. Thus, it would be prudent for investors to give due consideration to valuations and adopt a stock specific approach while investing in the sector.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407